



# BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, United States

Telephone: +1-925-223-8242 Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

## ESPS Peer-review Report

**Name of Journal:** World Journal of Diabetes

**ESPS Manuscript NO:** 8453

**Title:** Targeting inflammation in diabetes :Newer therapeutic options

**Reviewer code:** 00060192

**Science editor:** Song, Xiu-Xia

**Date sent for review:** 2013-12-28 19:31

**Date reviewed:** 2014-03-19 20:10

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input checked="" type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)		BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

## COMMENTS TO AUTHORS

A comprehensive Review on the therapeutic options on inflammation in diabetes mellitus.



# BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, United States

Telephone: +1-925-223-8242 Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

## ESPS Peer-review Report

**Name of Journal:** World Journal of Diabetes

**ESPS Manuscript NO:** 8453

**Title:** Targeting inflammation in diabetes :Newer therapeutic options

**Reviewer code:** 00058872

**Science editor:** Song, Xiu-Xia

**Date sent for review:** 2013-12-28 19:31

**Date reviewed:** 2014-03-20 02:25

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)		BPG Search:	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input checked="" type="checkbox"/> Minor revision
		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

## COMMENTS TO AUTHORS

Authors should be congratulated for their efforts. Unfortunately a great and important co-morbidity of T2DM is completely lacking, i.e., NAFLD. Authors should comment and quote the fact that T2DM is part of the MS, of which NAFLD is the main factor! What about non-alcoholic fatty liver disease as a new criterion to define metabolic syndrome? World J Gastroenterol. 2013 Jun 14;19(22):3375-84. doi: 10.3748/wjg.v19.i22.3375. PMID: 23801829 [PubMed - indexed for MEDLINE] Free PMC Article

The role of adiponectin in NAFLD. Should be evidenced and Authors should quote : What is the role of adiponectin in obesity related non-alcoholic fatty liver disease?. World J Gastroenterol. 2013 Feb 14;19(6):802-12. doi: 10.3748/wjg.v19.i6.802. PMID: 23430039

Authors should take into account that physical activity, linked to reduced expression of inflammatory cytokines is important in Diabetes-linked NAFLD. They should quote: Have guidelines addressing physical activity been established in nonalcoholic fatty liver disease?. World J Gastroenterol. 2012 Dec 14;18(46):6790-800. doi: 10.3748/wjg.v18.i46.6790.

Authors should add the following approach, quoting: Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease. World J Gastroenterol. 2012 Nov 7;18(41):5839-47. doi: 10.3748/wjg.v18.i41.5839. PMID: 23139599.

The imbalance between apoptosis and apoptosis in diabetes-linked NAFLD is important. authors should quote: Serum Bcl-2 concentrations in overweight-obese subjects with nonalcoholic fatty liver disease. World J Gastroenterol. 2011 Dec 28;17(48):5280-8. doi: 10.3748/wjg.v17.i48.5280. PMID: 22219597

The key link between IR and inflammation is expressed into the following papers that Authors should quote: JNKs, insulin resistance and inflammation: A possible link between NAFLD and coronary artery disease. World J Gastroenterol. 2011 Sep 7;17(33):3785-94. doi: 10.3748/wjg.v17.i33.3785. Review.



## BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, United States

Telephone: +1-925-223-8242 Fax: +1-925-223-8243

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com) <http://www.wjgnet.com>

---

PMID: 21987620 [ Spleen: A new role for an old player? World J Gastroenterol. 2011 Sep 7;17(33):3776-84. doi: 10.3748/wjg.v17.i33.3776. Review. PMID: 21987619 Auhors should not overlook the thromboembolism...and they should quote: High prevalence of nonalcoholic fatty liver in patients with idiopathic venous thromboembolism. Di Minno MN, Tufano A, Rusolillo A, Di Minno G, Tarantino G. World J Gastroenterol. 2010 Dec 28;16(48):6119-22. PMID: 21182227 Finally, the key links are the following that should be quoted. Hepatic steatosis, low-grade chronic inflammation and hormone/growth factor/adipokine imbalance. World J Gastroenterol. 2010 Oct 14;16(38):4773-83. Hepatic steatosis in overweight/obese females: new screening method for those at risk. World J Gastroenterol. 2009 Dec 7;15(45):5693-9. PMID: 19960566



# BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, United States

Telephone: +1-925-223-8242 Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

## ESPS Peer-review Report

**Name of Journal:** World Journal of Diabetes

**ESPS Manuscript NO:** 8453

**Title:** Targeting inflammation in diabetes :Newer therapeutic options

**Reviewer code:** 02708136

**Science editor:** Song, Xiu-Xia

**Date sent for review:** 2013-12-28 19:31

**Date reviewed:** 2014-03-24 12:52

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

## COMMENTS TO AUTHORS

Dear Authors: The importance of discovering new treatments to diabetes specially addressed to inflammation, controversial results and unknown details in the medical literature about this subject turn it to be a very interesting subject. However the manuscript needs main corrections. I annexed below my comments. 1- The English usage and grammar of the whole manuscript must be reviewed 2- Introduction: the aim of this review, and the methodology used to do it are lacking 3- Inflammation and diabetes: this title suggests pathophysiology of inflammation in diabetes but in the last 3 paragraphs, you described drugs effects. Maybe you could add another item to describe the action on inflammation of drugs usually used in diabetic patients. 4- Newer therapeutic options: I missed a pattern of drugs descriptions, I mean class, mechanism of action, studies results, whether they're used or not and their indications. . And I suggest you to review the title because when you say "Newer therapeutic options", it suggests that these are drugs that are already used to this proposal 5- Other emerging therapies: It's not very clear how you selected the drugs to this group as you included glitazones 6- Therapeutic treatments targeting inflammatory mediators in diabetic neuropathy/ nephropathy / retinopathy: I think it would be easier to the reader if you could begin briefly describing the mechanisms related to each complication and then results of studies using drugs directed to inflammation